Recently, based on the results of preclinical studies, a phase II clinical trial was conducted combining chlorpromazine 50 mg/day to the standard treatment with temozolomide in the sole adjuvant phase of the standard protocol in 41 diagnosed glioblastoma multiforme patients carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase (MGMT) gene [523]. The gene discussed is MGMT; the disease is glioblastoma.